Picture of Medistim ASA logo

MEDI — Medistim ASA News Story

0.000.00%
no flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Norway's Medistim Q3 revenue rises 25.9% on Americas strength

Norway's Medistim Q3 revenue rises 25.9% on Americas strength


Overview

  • Norway medical device maker's Q3 revenue rose 25.9% yr/yr to record MNOK 210.0

  • Q3 operating profit grew 55.7% yr/yr, with EBIT margin rising to 30.1%

  • Company declared quarterly dividend of NOK 2.50 per share


Outlook

  • Medistim did not provide specific guidance for future quarters or the full year in its press release


Result Drivers

  • OWN PRODUCTS SALES - Co said currency neutral sales of own products grew 34.6% in Q3, driving overall revenue growth

  • REGIONAL GROWTH - Co reported strong currency neutral sales growth in Americas (up 51.7%), APAC (up 44.6%) and EMEA (up 5.5%) in Q3

  • THIRD-PARTY SALES - Co said third-party distributor sales in Scandinavia increased 5.3% in Q3 but declined 13.0% YTD September


Company press release: ID:nObir1jJha


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

NOK 210 mln

Q3 EBIT

NOK 63.1 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

  • Wall Street's median 12-month price target for Medistim ASA is NOK332.50, about 18.3% above its October 22 closing price of NOK281.00

  • The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 28 three months ago


Reuters Recommended Reads

  • Oct 23 - Boule Diagnostics Q3 sales fall on weak instrument demand

  • Oct 22 - Sweden's Arjo Q3 revenue beats estimates, gross margin expands

  • Oct 22 - Sweden's XVIVO Q3 revenue beat expectations on thoracic sales


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Medistim ASA

See all news